Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Announces $3.4M in Additional Financing

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies said today it has closed on an additional $3.4 million in funding and committed financing, which it will use to continue development of its technology.

The financing includes $1.4 million in additional cash and $2 million in future commitments running through March 31, and finalizes Nuclea's Series B financing round. In October the company announced it raised $6.4 million in the round, and today's announcement brings the total Series B amount to $9.8 million.

Based in Pittsfield, Mass., Nuclea develops diagnostic assays based on fatty acid synthase, a biomarker for tumors. It said the funding will support its regulatory efforts in developing the technology, including clinical trials, facility upgrades, new hires, and general operations.

Nuclea CFO Robert Pierce said in a statement that the new round of financing is a "vital step" as it prepares to commercialize its tests. Last month the company said that it submitted premarket IDE filings with the US Food and Drug Administration for its breast cancer and prostate cancer assays.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.